CLAIMS

WE CLAIM::

1. A method of identifying a patient with a higher risk of preeclampsia comprising:
   a) assaying a sample from said patient to determine the level of a mRNA or other polynucleotide within said sample that hybridizes specifically to a polynucleotide of SEQ ID NO: 1-852; and
   b) comparing said level to a standard indicative of a higher risk of diagnosis of preeclampsia.

2. A method of identifying a patient with a higher risk of preeclampsia comprising:
   a) contacting a sample from said patient with an antibody that specifically binds to a polypeptide of SEQ ID NO 853-1704 to determine the level of polypeptide within said sample; and
   c) comparing said level to a standard indicative of a higher risk of diagnosis of preeclampsia.

3. The method of claim 1 or 2, wherein the specimen is serum.

4. The method of claim 1 or 2, wherein the specimen is plasma.

5. The method of claim 1 or 2, wherein the specimen is urine.

6. The method of claim 1 or 2, wherein the specimen is cervicovaginal mucous.

7. The method of claim 1 or 2, wherein the specimen is amniotic fluid.

8. The method of claim 1 or 2, wherein the specimen is fetal cells.

9. The method of claim 1, wherein said nucleotides further comprise any polymorphism or splice variants of the polynucleotide sequences of SEQ ID 1-852.

10. The method of claim 2, wherein said proteins further comprise any fragments of the polypeptide sequences of SEQ ID 853-1704.

11. A diagnostic kit for detecting preeclampsia comprising:

a) an antibody specific for any of the polypeptides of SEQ ID 853-1704 or fragments thereof; and

b) a standard for any of the polypeptides of SEQ ID 853-1704 indicative of a higher risk of diagnosis of preeclampsia.

12. A diagnostic kit for detecting preeclampsia comprising:

a) a polynucleotide sequence comprising any of SEQ ID 1-852 coupled to a surface; and

b) A standard for any of the polynucleotides of SEQ ID 1-852 indicative of a higher risk of diagnosis of preeclampsia.

13. A pharmaceutical composition comprising an antibody specific for any of the polypeptides of SEQ ID NO: 853-1704, effective to ameliorate signs or symptoms of preeclampsia.

14. The pharmaceutical composition of claim 13, wherein said antibody is a monoclonal antibody or fragment thereof.

15. A pharmaceutical composition comprising one or more purified polypeptides of SEQ ID NO: 853-1704, effective to ameliorate signs or symptoms of preeclampsia.

16. A method of treating preeclampsia comprising the steps of:

a) detecting increased levels of any of the polynucleotides of SEQ ID NO: 1-852 or the polypeptides of SEQ ID NO: 853-1704 in preeclamptic sample specimens; and

b) administering an effective dose of any of said compositions as in claims 13 or 14.

17. A method of treating preeclampsia comprising the steps of:

a) detecting decreased levels of any of the polynucleotides of SEQ ID NO: 1-852 or the polypeptides of SEQ ID NO: 853-1704 in preeclamptic sample specimens; and

b) administering an effective dose of any of said compositions as in claim 15.